Nijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
Scroll
View
Swipe
Play
Jun 2026
Synthon Announces Investment from Goldman Sachs Alternatives
With Goldman Sachs Alternatives as its key partner, Synthon will focus on accelerating its next stage of growth, including both advancing the success of its existing product portfolio as well as developing and launching new, complex medicines. Leveraging its differentiated, science-backed, intellectual propertydriven development platform, the Company is well-positioned to continue delivering on its mission of enabling affordable medicines for patients globally.
Anish Mehta, Synthon CEO, said: “The closing of this transaction marks an exciting new chapter for Synthon. We are proud of the momentum that we have built and are delighted to have Goldman Sachs Alternatives as our new partner. Working together, along with our more than 1,600 dedicated and talented colleagues around the world, I am excited about the next phase of our growth journey and look forward to maximizing patient impact by accelerating our growth, improving our operational network, and advancing our R&D platforms and capabilities for increasingly complex generics.”
About Synthon
Synthon is a vertically integrated, global leader in the development and manufacturing of complex generics. For over three decades, the Company has established a proven track record of launching differentiated, complex products at market formation. Synthon has a global footprint with direct presence in eight countries, including four R&D labs as well as four manufacturing sites located in Spain, Czech Republic, Argentina, and Chile. The Company is headquartered in the Netherlands and has approximately
1,600 employees. With a portfolio of over 70 molecules, and diversified base of more than 200 customers serving around 100 countries, Synthon is delivering on its mission of Enabling Affordable Medicines Globally.
Follow us on LinkedIn.
For further information, please visit https://www.synthon.com/
About Private Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $500 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and openarchitecture programs.
The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.
The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has approximately $3.2 trillion in assets under supervision globally as of March 31, 2025.
Established in 1986, Private Equity at Goldman Sachs Alternatives has invested over $75 billion since inception. The business combines a global network of relationships, unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across its portfolios.
About BC Partners
BC Partners (www.bcpartners.com) BC Partners is a leading investment firm with circa €40 billion inassets under management across private equity, private debt, and real estate strategies. Established in 1986, BC Partners has played an active role for over three decades in developing the European buy-out market. Today BC Partners integrated transatlantic investment teams work from offices in Europe and North America and are aligned across our four core sectors: TMT, Healthcare, Services & Industrials, and Consumer. Since its foundation, BC Partners has completed over 128 private equity investments in companies with a total enterprise value of over €170 billion and is currently investing its eleventh private equity buyout fund. BC Partners was voted Mid-Market Firm of the Year 2024 by Private Equity International.
Follow us on LinkedIn.
Media Contacts
For Synthon
info@synthon.com
T +31 24 372 77 00
For Goldman Sachs Alternatives
Noa Asselbergs
Noa.Asselbergs@gs.com
T +31 6 43801459